A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)

Trial Profile

A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Selinexor (Primary)
  • Indications Malignant thymoma
  • Focus Therapeutic Use
  • Acronyms SELECT
  • Most Recent Events

    • 06 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 12 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Mar 2018.
    • 17 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top